Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 2)

[marvessa]

Antwort auf Beitrag Nr.: 75.908.049 von XC_2011 am 07.06.24 12:10:57

0.33 cdn sind 0.22 Euro , Germany hat es vorweggenommen

[XC_2011]

Antwort auf Beitrag Nr.: 75.907.953 von marvessa am 07.06.24 12:01:07

Zitat von marvessa: Wir sind ja schon auf KE Kurs

Glaube nicht, dass die 0.36 CAD halten. Wir werden sehen, wo die Holzfäller heute schliessen! Ich habe mein Körbchen aufgestellt, weit unter den 0.36. Sollte ich sie nicht bekommen, macht es auch nichts. Habe das Sernova Geld als ich ausgestiegen bin, nochmals in einen Biotech Titel investiert, wo ich seit Monaten erfolgreich unterwegs bin.

[marvessa]

Antwort auf Beitrag Nr.: 75.907.953 von marvessa am 07.06.24 12:01:07

Frage ist wie lange reicht dieses Geld , ich hab ne Aktie die ging auch auf KE Kurs runter ist danach aber mehr als 100 Prozent hoch

[marvessa]

Antwort auf Beitrag Nr.: 75.907.860 von XC_2011 am 07.06.24 11:53:40

Wir sind ja schon auf KE Kurs

[XC_2011]

Es ist halt so bei Biotech, von 10 gehen 7 in die Hosen. Sernova gehört leider auch dazu. Ich bin bei mehreren investiert, bei einem Titel sehr erfolgreich, bei den anderen eher mässig. Mit dem einen Titel kann ich die Verluste bei Sernova locker wegstecken.

Frage ist hier wann soll man wieder einsteigen? Nach der KE Ankündigung gibt es sicher genug Gelegenheiten wieder günstig einzusteigen. Warte jetzt mal ab, was in den nächsten Tagen passiert.

[wallander08]

Ein PP wer hatte den da ,so einen Blackout.
😂
PS: es wurde so viel erzählt manche träumen von 25 Euro

[marvessa]

Wurde nicht erzählt Evotec sicher schon raus ? 😏

[ooy]

Sernova Announces Marketed Public Offering of Units
Canada NewswireJun 6, 2024 4:17 PM EDT
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

LONDON, ON and BOSTON , June 6, 2024 /CNW/ - Sernova Corp. (" Sernova " or the " Company ") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) is pleased to announce that it has filed a preliminary short form prospectus in connection with a best efforts marketed public offering (the " Offering ") of units of the Company (the " Units "). The Offering is being led by Stifel Nicolaus Canada Inc., as lead agent (the " Lead Agent ") and joint bookrunner with Leede Jones Gable Inc., on behalf of a syndicate of agents that includes Ventum Financial Corp., Raymond James , Research Capital Corporation and Roth Canada, Inc. (together with the Lead Agent, the " Agents ") and is for minimum gross proceeds of $6,500,000 and up to maximum gross proceeds of $10,000,000 . Each Unit will be offered at a price of $0.33 per Unit (the " Offering Price "), and shall consist of one (1) common share of the Company (each, a " Common Share ") and one (1) Common Share purchase warrant (a " Warrant "). Each Warrant will entitle the holder to purchase one Common Share (each, a " Warrant Share ") at an exercise price of $0.40 per Warrant Share for 36 months. It is expected that a definitive agency agreement will be entered into between the Company and the Agents following the successful marketing of the Offering.

The Company has agreed to grant the Agents an option (the " Over-Allotment Option ") to sell up to an additional number of Units at the Offering Price as is equal to 15% of the number of Units issued pursuant to the Offering, exercisable in whole or in part, at any time and from time to time on or prior to the date that is 30 days following the Closing Date (as defined below) to cover over-allotments, if any, and for market stabilization purposes. The Over-Allotment Option shall be exercisable for any number of Units, Common Shares, Warrants, or any combination thereof at a price equal to the Offering Price for a Unit and a price to be agreed upon for the Common Shares and Warrants.

The Company plans to use the net proceeds from the offering to expand enrollment in the Company's phase I/II Human Donor Islet clinical study, to support the Company's R&D activities and for general corporate purposes. In addition Sernova would like to announce that Evotec SE, its largest shareholder and collaboration partner, will participate in the offering.

The Offering is scheduled to close on or about June 20, 2024 (the " Closing Date "), and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange (the " Exchange ").

A preliminary short form prospectus containing important information relating to the Offering has been filed with the securities regulatory authorities in each of the provinces in Canada , other than the Province of Québec, and is still subject to completion or amendment. The preliminary short form prospectus is available via SEDAR+ at www.sedarplus.ca . Alternatively, the Company, any Agent or any dealer participating in the Offering will arrange to send you the preliminary short form prospectus upon request from the Lead Agent at [e-mail] .

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States . The securities have not been and will not be registered under the United States Securities Act of 1933 , as amended (the " U.S. Securities Act "), or any U.S. state securities laws and may not be offered or sold to or for the account or benefit of persons in the "United States " or "U.S. persons" (as such terms are defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

[scoobydoobidoo]

Aber hat nicht eine C.B. behauptet ( in ein sehr glaubwürdiges Mail) dass es KEINE KE gibt.

Und jetzt sehen wir auch mal wieder dass solche Mails hier mit Recht nicht zugelassen sind.

[J285607]

So, morgen geht’s hier erstmal eine Etage tiefer!

Das nä. PP kommt.